Unfractionated heparin (UFH) is a naturally occurring, highly sulfated glycosaminoglycan (GAG) extracted from porcine intestinal mucosa or bovine lung, with a molecular weight ranging from 3,000 to 30,000 daltons (Da) and a mean of approximately 15,000 Da. Its anticoagulant activity is entirely indirect, dependent on the plasma protein antithrombin III (AT-III), and its highly heterogeneous molecular composition produces unpredictable, nonlinear pharmacokinetics that necessitate laboratory monitoring. Despite these limitations, UFH remains the anticoagulant of choice in specific high-acuity clinical settings because of its short half-life, its ready reversibility with protamine sulfate, and its applicability in patients with severe renal impairment.
Mechanism of Action. The anticoagulant activity of UFH resides in a specific pentasaccharide sequence present in approximately one-third of heparin molecules. This high-affinity pentasaccharide binds to a lysine-rich region on AT-III, inducing a conformational change in AT-III that exposes its reactive site loop and converts AT-III from a slow, progressive inhibitor to a rapid inhibitor of coagulation serine proteases. The accelerated AT-III inhibits thrombin (factor IIa, FIIa) and factor Xa (FXa) with roughly equal potency, as well as factor IXa (FIXa), factor XIa (FXIa), and factor XIIa (FXIIa) to a lesser degree. For thrombin inhibition specifically, heparin must simultaneously bind both AT-III and thrombin through ionic interactions involving thrombin's heparin-binding exosite II, forming a ternary heparin-AT-III-thrombin complex; this bridging requirement means that only heparin chains of at least 18 saccharide units are capable of inhibiting thrombin. For FXa inhibition, the pentasaccharide sequence alone is sufficient, without bridging to FXa, which is why shorter heparin fragments retain anti-FXa activity but not anti-IIa activity.1
Beyond its primary AT-III-dependent mechanism, UFH releases tissue factor pathway inhibitor (TFPI) from endothelial cell heparan sulfate proteoglycans into the circulation, contributing an additional anticoagulant mechanism independent of AT-III. UFH also binds to von Willebrand factor (vWF) and inhibits platelet function at high concentrations, contributing to the hemorrhagic risk seen at supratherapeutic doses. These secondary pharmacodynamic effects are dose-dependent and contribute to the complexity of heparin's clinical pharmacology.1
Pharmacokinetics and Nonlinearity. UFH pharmacokinetics are governed by two simultaneous clearance mechanisms operating in parallel: a rapid, saturable, dose-dependent mechanism mediated by binding to endothelial cells and macrophages (which internalize and depolymerize heparin), and a slower, first-order renal clearance mechanism. At low doses, the saturable cellular clearance pathway dominates, resulting in a short apparent half-life of approximately 30 minutes. At higher doses, the cellular clearance pathway saturates and the pharmacokinetics shift toward first-order, extending the half-life to 60 to 90 minutes. This produces the clinically important phenomenon of dose-dependent nonlinearity: the anticoagulant effect increases disproportionately with increasing dose. A doubling of the UFH dose does not produce a doubling of the anticoagulant effect; it produces a greater-than-proportional prolongation of the activated partial thromboplastin time (aPTT). This nonlinearity means that dose titration by weight-based algorithms with aPTT-guided adjustment is mandatory for therapeutic anticoagulation with UFH.1,3
Protein Binding and Variability. UFH binds extensively and non-specifically to a large number of plasma proteins in addition to AT-III, including vitronectin, fibronectin, von Willebrand factor, platelet factor 4 (PF4), lipoproteins, histidine-rich glycoprotein, and acute-phase reactant proteins. This nonspecific protein binding has several clinically significant consequences. First, only the fraction of heparin not bound to non-AT-III proteins is pharmacologically active, and this fraction varies substantially between patients, particularly in inflammatory states where elevated levels of PF4 (released from activated platelets) and other heparin-binding proteins reduce heparin availability. Second, the high degree of interpatient variability in protein binding underlies the well-documented variability in aPTT response to fixed heparin doses, requiring individualized weight-based dosing and frequent monitoring. Third, the phenomenon of heparin resistance, defined as the requirement for more than 35,000 international units (IU) per day to achieve a therapeutic aPTT, most commonly reflects elevated heparin-binding proteins (particularly PF4 in patients with active thrombosis or post-cardiopulmonary bypass) or AT-III deficiency, rather than true pharmacodynamic insensitivity.1,3
Administration and Clinical Pharmacology. UFH is administered intravenously (IV) for therapeutic anticoagulation in acute settings, or subcutaneously (SC) for prophylaxis. IV UFH provides immediate anticoagulation; SC UFH has a delayed onset of 1 to 2 hours and reduced bioavailability of approximately 20 to 30% at prophylactic doses. UFH is not absorbed orally. The standard approach to therapeutic IV anticoagulation uses a weight-based nomogram: a bolus dose of 80 IU per kilogram (IU/kg), followed by an infusion of 18 IU/kg per hour, with subsequent aPTT-guided adjustment.3 The target aPTT therapeutic range corresponds to a heparin level of 0.3 to 0.7 IU (international units)/mL by anti-Xa assay, typically corresponding to an aPTT of 60 to 100 seconds depending on the reagent used in a given laboratory. Because the aPTT therapeutic range is reagent-dependent, each institution must validate its own therapeutic aPTT range against the anti-Xa assay. UFH requires no dose adjustment for renal impairment, as clearance is not primarily renal at therapeutic doses, making it the preferred anticoagulant in patients with severe acute kidney injury (AKI) or creatinine clearance (CrCl) below 30 mL/min where LMWH (low-molecular-weight heparin) would accumulate.1
Mechanism: AT-III-dependent inhibition of FIIa and FXa (equal potency); requires chains of at least 18 saccharides for thrombin inhibition. Dosing: 80 IU/kg bolus, 18 IU/kg/hr infusion (therapeutic); adjust to aPTT 60–100 seconds (reagent-dependent). Half-life: 30 min (low dose) to 90 min (high dose); nonlinear kinetics. Monitoring: aPTT every 6 hours until two consecutive therapeutic values, then every 24 hours. No renal dose adjustment required. Reversal: protamine sulfate 1 mg per 100 IU UFH given in last 2–4 hours (maximum 50 mg; slow IV infusion to avoid hypotension).
Low-molecular-weight heparins (LMWHs) are produced by controlled chemical or enzymatic depolymerization of UFH (unfractionated heparin), yielding fragments with a mean molecular weight of 4,000 to 6,000 Da. This smaller size dramatically alters the pharmacological profile relative to UFH: the anti-Xa to anti-IIa activity ratio shifts from approximately 1:1 for UFH to 2:1 to 4:1 for most LMWHs, protein binding is substantially reduced, the pharmacokinetic profile becomes linear and predictable, and bioavailability after subcutaneous injection exceeds 90%. These properties translate directly into the clinical advantages of fixed weight-based dosing, once- or twice-daily administration, and the elimination of routine laboratory monitoring for most patients.
Molecular Basis of LMWH Activity. LMWH (low-molecular-weight heparin) molecules that contain the critical pentasaccharide sequence retain the ability to accelerate AT-III (antithrombin III) inhibition of FXa, because FXa inhibition requires only the pentasaccharide-AT-III complex without bridging. However, because the majority of LMWH chains are fewer than 18 saccharide units in length, most LMWH molecules are too short to simultaneously bridge AT-III and thrombin. The result is preferential anti-FXa activity with reduced anti-IIa activity compared to UFH. The specific anti-Xa to anti-IIa ratio differs between LMWH preparations: enoxaparin (Lovenox) has a ratio of approximately 3.8:1; dalteparin (Fragmin) approximately 2.7:1; tinzaparin (Innohep) approximately 1.9:1, reflecting differences in the depolymerization technique and resulting chain length distribution. These pharmacodynamic differences have not been shown to translate into clinically significant differences in efficacy or safety between LMWH preparations in most head-to-head trials, though tinzaparin's higher anti-IIa activity has led to some interest in its use in specific settings such as cancer-associated thrombosis.5
Pharmacokinetics of LMWHs. The dramatically reduced protein binding of LMWHs compared to UFH is the pharmacokinetic cornerstone of their clinical advantages. Because LMWHs bind less avidly to endothelial cells and plasma proteins other than AT-III, a larger and more consistent proportion of the administered dose is pharmacologically available. Clearance is primarily renal, occurring through glomerular filtration of the smaller molecular weight fragments; this renal clearance mechanism is linear (first-order) and predictable, yielding a half-life of 3 to 6 hours for most LMWHs administered subcutaneously. Subcutaneous bioavailability exceeds 90%, permitting weight-based fixed dosing without IV administration for most indications. The linear pharmacokinetics mean that doubling the dose produces a proportional doubling of anticoagulant effect, enabling predictable once-daily (dalteparin, tinzaparin) or twice-daily (enoxaparin) dosing without routine monitoring in patients with normal renal function and body weight in the standard range.24,5
Renal Dosing and Monitoring Considerations. Because LMWH clearance is primarily renal, accumulation occurs in patients with reduced CrCl, leading to supratherapeutic anti-Xa levels and increased bleeding risk. Enoxaparin, the most widely used LMWH, requires dose reduction for therapeutic anticoagulation in patients with CrCl below 30 mL/min: the twice-daily therapeutic dose of 1 mg/kg every 12 hours is reduced to 1 mg/kg every 24 hours, and the single daily prophylactic dose of 40 mg daily is reduced to 30 mg daily. In patients with CrCl below 15 mL/min, dalteparin and tinzaparin are preferred over enoxaparin for extended therapy because limited data suggest less accumulation, though the evidence base is limited and UFH remains the safest choice in severe renal impairment. Anti-Xa monitoring, with a target peak (4 hours post-dose) level of 0.6 to 1.0 IU (international units)/mL for twice-daily dosing and 1.0 to 2.0 IU/mL for once-daily dosing, is recommended in populations where LMWH pharmacokinetics may be altered: patients with CrCl 15 to 30 mL/min, weight above 100 kg or below 50 kg, pregnancy, and pediatric patients.458
Fondaparinux. Fondaparinux (Arixtra) is a synthetic pentasaccharide that represents the minimal structural unit of heparin required for AT-III binding. As a pure pentasaccharide, it selectively accelerates AT-III inhibition of FXa only; it has no ability to bridge AT-III to thrombin and therefore produces no direct thrombin inhibition. The anti-Xa to anti-IIa ratio is theoretically infinite. Because fondaparinux is entirely synthetic and does not contain the additional polymer sequences responsible for heparin-platelet factor 4 (PF4) immune complex formation, it does not cause heparin-induced thrombocytopenia (HIT) type II and is a therapeutic option in patients with a history of HIT who require anticoagulation for indications where parenteral anti-Xa activity is appropriate. Fondaparinux is administered subcutaneously once daily; its bioavailability after subcutaneous injection is 100%, and its half-life of 17 to 21 hours enables once-daily dosing with predictable anticoagulation. Clearance is entirely renal, and fondaparinux is absolutely contraindicated when CrCl is below 30 mL/min due to accumulation and bleeding risk. Because protamine sulfate does not neutralize fondaparinux and no approved reversal agent exists, bleeding management relies on discontinuation and supportive measures; andexanet alfa has some activity against fondaparinux in vitro but is not approved for this indication.67
UFH: anti-Xa = anti-IIa (1:1); nonlinear PK; requires aPTT monitoring; reversible with protamine; preferred in severe renal impairment (CrCl <30 mL/min) and when rapid reversibility is needed. LMWHs: anti-Xa > anti-IIa (2:1 to 4:1); linear PK; subcutaneous; no routine monitoring in standard patients; anti-Xa monitoring in renal impairment, extremes of weight, pregnancy; partially reversible with protamine (70–80% anti-Xa reversal). Fondaparinux: anti-Xa only; 100% SC bioavailability; once daily; no HIT risk; no protamine reversal; contraindicated CrCl <30 mL/min.
Rational monitoring of heparin-based anticoagulants requires understanding both the pharmacokinetic rationale for each assay and its limitations. The aPTT and the anti-Xa assay measure different aspects of heparin activity and are not interchangeable. Selecting the appropriate assay, target range, and monitoring frequency for a given patient and clinical context is a core clinical skill in inpatient anticoagulation management.
aPTT Monitoring for UFH (unfractionated heparin). The activated partial thromboplastin time (aPTT) measures the time for clot formation in plasma after contact activation, reflecting the activity of the intrinsic and common coagulation pathways. UFH prolongs the aPTT by inhibiting thrombin and FXa within these pathways via AT-III (antithrombin III). The aPTT is the standard monitoring test for therapeutic IV UFH because it is widely available, inexpensive, and reflects the functional anticoagulant state in real time. The standard therapeutic aPTT range of 60 to 100 seconds corresponds to a heparin level of 0.3 to 0.7 IU (international units)/mL by anti-Xa assay in most laboratory systems, but this correspondence is reagent-specific and must be validated locally. Important limitations of aPTT monitoring include: (1) the aPTT may be abnormally prolonged at baseline in patients with lupus anticoagulant, factor deficiencies, or antiphospholipid antibodies, making it unreliable for monitoring in these patients; (2) fibrinogen levels, factor VIII levels, and acute-phase reactants affect the aPTT independent of heparin; and (3) the aPTT is insensitive to heparin at low concentrations used for prophylaxis, meaning it cannot be used to monitor subcutaneous prophylactic UFH. In patients with baseline aPTT elevation or when aPTT-heparin correlation is unreliable, anti-Xa monitoring is preferred.5
Anti-Xa Monitoring. The anti-Xa assay measures inhibition of FXa activity in plasma, providing a direct functional measurement of the fraction of heparin activity mediated through AT-III. Unlike the aPTT, the anti-Xa assay is not affected by elevated factor VIII, low fibrinogen, lupus anticoagulant, or most coagulation factor deficiencies, making it more reliable in patients with these confounders. For UFH monitoring, the therapeutic anti-Xa target is 0.3 to 0.7 IU/mL drawn 6 hours after any infusion rate change. For LMWH (low-molecular-weight heparin) monitoring (when indicated), peak anti-Xa levels are drawn 4 hours after subcutaneous injection: the therapeutic target for twice-daily dosing is 0.6 to 1.0 IU/mL; for once-daily dosing the target is 1.0 to 2.0 IU/mL. Trough anti-Xa levels (drawn just before the next dose) can be used to detect accumulation in patients at risk; a trough above 0.5 IU/mL for twice-daily dosing suggests accumulation and indicates dose reduction or frequency change. Fondaparinux is monitored by anti-Xa assay when monitoring is indicated, using fondaparinux-calibrated reagents, with a therapeutic target of 0.6 to 1.3 IU/mL in most clinical applications.6,8
Weight-Based Dosing and Obesity. Heparin-based anticoagulants are dosed by total body weight (TBW) in standard patients. In obese patients (typically defined as body mass index (BMI) above 40 kg/m2 or weight above 120 kg), weight-based dosing becomes more complex. For UFH, TBW-based dosing is appropriate because the volume of distribution tracks with TBW and supratherapeutic bolus doses are less likely at higher weights; TBW capped at 165 kg is used by some institutions to avoid extreme bolus doses. For enoxaparin, TBW-based dosing at 1 mg/kg every 12 hours is appropriate up to approximately 150 to 160 kg, with anti-Xa monitoring recommended above this threshold to confirm therapeutic levels. In morbid obesity, some data support using adjusted body weight (AdjBW = ideal body weight (IBW) + 0.4 times (TBW minus IBW)) for enoxaparin dosing above 100 kg to avoid supratherapeutic levels, but practice varies between institutions and anti-Xa verification is the safest approach. In underweight patients (less than 50 kg), standard weight-based enoxaparin doses may produce supratherapeutic anti-Xa levels, and anti-Xa monitoring is similarly recommended.5,8
Heparin in Pregnancy. Heparins are the anticoagulants of choice throughout pregnancy because they do not cross the placenta and do not cause fetal anticoagulation or teratogenesis. LMWHs are preferred over UFH for most indications in pregnancy due to their predictable pharmacokinetics, subcutaneous administration, and superior maternal tolerability; UFH retains a role in specific situations including immediately peripartum when rapid reversal may be needed. Warfarin is contraindicated in the first trimester (embryopathy risk at 6 to 12 weeks) and relatively contraindicated in the third trimester (fetal bleeding risk); DOACs are contraindicated throughout pregnancy due to lack of safety data and potential for placental transfer. Anti-Xa monitoring of LMWH is recommended in pregnancy because the volume of distribution increases with advancing gestational age and renal clearance increases due to physiological hyperfiltration, both of which may reduce anti-Xa levels and require dose escalation, particularly in the second and third trimesters. LMWH should be held 24 hours before planned delivery or neuraxial anesthesia; UFH should be held 4 to 6 hours before.6,9
UFH therapeutic IV: aPTT 60–100 sec (reagent-dependent) or anti-Xa 0.3–0.7 IU/mL; draw 6h after rate change. LMWH twice-daily: anti-Xa peak (4h post-dose) 0.6–1.0 IU/mL; indicate monitoring in CrCl <30, weight >100 kg or <50 kg, pregnancy. LMWH once-daily: anti-Xa peak 1.0–2.0 IU/mL. Fondaparinux: anti-Xa 0.6–1.3 IU/mL (fondaparinux-calibrated). Anti-Xa preferred over aPTT when: lupus anticoagulant present, baseline aPTT elevated, patient has antiphospholipid antibodies, high acute-phase reactants.
Heparin-induced thrombocytopenia (HIT) is one of the most clinically dangerous drug-induced immune reactions in medicine. Its defining paradox is that an anticoagulant causes a prothrombotic state; the same antibodies that deplete platelets through immune-mediated clearance simultaneously activate them, generating a thrombin burst that can produce catastrophic arterial and venous thrombosis. Recognizing HIT promptly and managing it correctly are critical clinical competencies for anyone prescribing heparin.
Type I vs Type II HIT. Two distinct syndromes are designated HIT. Type I HIT (also called heparin-associated thrombocytopenia, HAT) is a non-immune, direct pharmacological effect of heparin on platelets that occurs in up to 10% of patients receiving UFH (unfractionated heparin). It appears within the first 1 to 2 days of heparin exposure, produces a mild, transient platelet count decrease (rarely below 100 x 109/L), is not associated with thrombosis, and resolves spontaneously without any change in heparin therapy. Type I HIT is benign and requires no specific intervention. Type II HIT is a distinct, immune-mediated syndrome caused by antibodies to a complex of PF4 (platelet factor 4) and heparin. Type II HIT occurs in 0.1 to 5% of patients exposed to heparin (higher incidence with UFH than LMWH (low-molecular-weight heparin); lowest with fondaparinux), typically develops 5 to 14 days after heparin initiation (or within hours of re-exposure in patients with recent prior heparin exposure and persistent antibodies), and is associated with a 20 to 50% risk of thrombosis. All subsequent references to HIT in this module refer to Type II HIT unless otherwise specified.1011
Pathophysiology of Type II HIT. The pathophysiology of Type II HIT begins with heparin binding to PF4 (platelet factor 4), a highly cationic chemokine released from platelet alpha-granules during platelet activation. Heparin, a polyanion, forms an electrostatic complex with PF4, a polycation, producing a neo-antigen on the PF4 surface that is recognized as foreign by the immune system. In susceptible individuals, immunoglobulin G (IgG) antibodies against the PF4-heparin complex are generated, typically within 5 to 14 days of heparin exposure. These HIT antibodies have two pathological consequences: first, the IgG Fc region of the bound antibody cross-links Fc-gamma receptor IIA (FcgRIIA) on the platelet surface, activating platelets and triggering platelet aggregation, release of additional PF4, and generation of platelet-derived procoagulant microparticles; second, the HIT immune complex binds to monocytes and endothelial cells via their FcgRIIA receptors, generating tissue factor expression and further amplifying thrombin generation. The result is a massively prothrombotic state despite thrombocytopenia, explaining the counterintuitive syndrome of thrombocytopenia with thrombosis. Heparin of any source, route, or dose can trigger HIT; even heparin flushes of IV catheters at doses of 10 to 100 IU (international units) are sufficient to sustain the prothrombotic process once HIT antibodies are present.10,11
Clinical Presentation. The classic presentation of HIT is a platelet count fall of 50% or more from the baseline value, occurring 5 to 14 days after heparin initiation, in association with thrombosis or thromboembolic complications. The platelet nadir is typically 20 to 150 x 109/L; severely low counts below 20 x 109/L are unusual and should prompt consideration of alternative diagnoses. Thrombosis complicates HIT in 20 to 50% of untreated cases and is the primary cause of morbidity and mortality. Both venous and arterial thrombosis occur, though venous thrombosis (DVT [deep vein thrombosis], PE [pulmonary embolism], adrenal vein thrombosis) is more common than arterial thrombosis (limb arterial occlusion, stroke, myocardial infarction). Limb gangrene in the setting of a falling platelet count on heparin is a medical emergency requiring immediate heparin cessation and non-heparin anticoagulation. Skin necrosis at heparin injection sites can occur as a distinct manifestation. Anaphylactoid reactions after IV heparin bolus (fever, chills, hypertension, tachycardia, cardiac arrest) may represent a manifestation of HIT in patients with pre-formed antibodies from recent prior heparin exposure.10,11
The 4T Score. The 4T score is a validated clinical pretest probability tool for HIT that assigns points in four categories: Thrombocytopenia (magnitude and pattern of platelet fall), Timing (onset relative to heparin exposure), Thrombosis (presence and type), and Other causes of thrombocytopenia (absence of alternative explanations). Each category contributes 0 to 2 points, for a maximum score of 8. A score of 0 to 3 indicates low probability of HIT, with a negative predictive value exceeding 99%, effectively ruling out HIT and permitting continued heparin use with monitoring. A score of 4 to 5 indicates intermediate probability; heparin should be discontinued and laboratory testing initiated. A score of 6 to 8 indicates high probability; heparin must be stopped immediately and empirical alternative anticoagulation initiated before laboratory results are available, given the risk of catastrophic thrombosis with continued heparin exposure. The 4T score has limitations: interobserver variability exists in scoring the thrombocytopenia and timing categories, and the score may underperform in intensive care unit (ICU) patients where multiple causes of thrombocytopenia coexist.1112
Laboratory Diagnosis. Laboratory confirmation of HIT requires either an immunological assay or a functional assay, and ideally both are used to establish the diagnosis. The enzyme-linked immunosorbent assay (ELISA) for anti-PF4-heparin IgG antibodies (or IgG/IgM/IgA combined) is highly sensitive (greater than 95%) but has lower specificity (approximately 50 to 90%), as PF4-heparin antibodies can be generated in up to 50% of patients post-cardiac surgery and 20% of patients post-orthopedic surgery without causing clinical HIT. An IgG-specific ELISA has higher specificity than a polyspecific assay because only IgG antibodies are pathogenic in HIT. A high optical density (OD) value on the ELISA (OD above 1.0 to 2.0 depending on the assay) correlates more strongly with functional platelet-activating capacity and clinical HIT. The serotonin release assay (SRA), considered the gold standard functional test, measures whether patient plasma containing putative HIT antibodies activates washed, serotonin-loaded normal donor platelets in the presence of therapeutic concentrations of heparin; a positive SRA (greater than 20% serotonin release) confirms platelet-activating HIT antibodies with specificity exceeding 95%. Because the SRA is technically demanding, requires fresh radioactive-label platelets, and is not widely available, the ELISA is the practical first-line test, with SRA confirmation used when the diagnosis is uncertain or has major management implications.11,12
Thrombocytopenia: 2 pts = >50% fall or nadir 20–100; 1 pt = 30–50% fall or nadir 10–19; 0 pts = <30% fall or nadir <10. Timing: 2 pts = days 5–10 or ≤1 day with prior heparin 30–100 days; 1 pt = >10 days or ≤1 day with prior heparin >100 days; 0 pts = <4 days without recent heparin. Thrombosis: 2 pts = new confirmed thrombosis or skin necrosis; 1 pt = progressive thrombosis or suspected; 0 pts = none. Other causes: 2 pts = none apparent; 1 pt = possible other cause; 0 pts = definite other cause. Score 0–3: low (<1% HIT); 4–5: intermediate (10–30%); 6–8: high (>80%).
The management of confirmed or suspected HIT (heparin-induced thrombocytopenia) requires two simultaneous actions: immediate cessation of all heparin in any form and initiation of alternative non-heparin anticoagulation at therapeutic doses. The second action is as mandatory as the first, because the prothrombotic state of HIT persists for days to weeks after heparin discontinuation, and thrombosis risk remains extremely high without active anticoagulation. The choice of alternative anticoagulant, the approach to reversal when needed, and the transition to long-term oral anticoagulation require understanding the pharmacology of several additional agents.
Immediate HIT Management: Stop All Heparin. When HIT is suspected (4T score 4 or above, or clinical gestalt), all heparin must be stopped immediately regardless of indication and regardless of the heparin dose, route, or formulation. This includes UFH (unfractionated heparin) infusions, LMWH (low-molecular-weight heparin) injections, heparin flushes of IV or arterial lines, heparin-coated catheters, and heparin in dialysis circuits. LMWH does not constitute an appropriate alternative anticoagulant in HIT because LMWH cross-reacts with HIT antibodies in approximately 90% of cases and can perpetuate platelet activation. Fondaparinux is not cross-reactive with HIT antibodies in vitro (consistent with its inability to cause HIT de novo) and has been used in HIT management, but it lacks prospective trial evidence specifically in the HIT setting and does not have a regulatory approval for this indication. The direct thrombin inhibitors argatroban and bivalirudin are the first-line alternative anticoagulants in HIT in the United States.10,11,12
Argatroban in HIT. Argatroban is a synthetic, small-molecule, reversible direct thrombin inhibitor (DTI) that binds directly to the thrombin active site, inhibiting all thrombin-mediated reactions including fibrinogen cleavage, factor V (FV) and factor VIII (FVIII) activation, platelet PAR-1 (protease-activated receptor 1) activation, and factor XIII (FXIII) activation. Unlike heparins, argatroban does not require AT-III (antithrombin III) for its anticoagulant effect, making it fully effective in patients with AT-III deficiency including HIT patients with consumptive AT-III reduction. Argatroban is metabolized entirely by the liver through hydroxylation and aromatization via cytochrome P450 (CYP) 3A4/5 enzymes; it does not require renal excretion, making it the preferred DTI in patients with renal failure or renal impairment. The standard dosing for non-ICU patients is 2 micrograms (mcg)/kg/min as a continuous IV infusion, titrated to a target aPTT of 1.5 to 3 times the baseline value (typically 45 to 90 seconds). In seriously ill patients and those with hepatic impairment, the starting dose is reduced to 0.5 to 1.0 mcg/kg/min to avoid supratherapeutic levels.13
An important pharmacological interaction specific to argatroban: it prolongs the PT/INR (prothrombin time/international normalized ratio) independently of vitamin K-dependent factor levels, so the INR on argatroban is elevated above what vitamin K antagonist (VKA) therapy alone would produce. When transitioning from argatroban to warfarin, a combined argatroban-plus-warfarin INR target of 4.0 or above (for patients taking warfarin doses expected to produce a therapeutic INR of 2.0 to 3.0 when used alone) is required before argatroban can be discontinued; the chromogenic factor X assay provides a more reliable assessment of warfarin effect than INR during argatroban overlap.12,13
Bivalirudin in HIT. Bivalirudin (Angiomax) is a 20-amino acid synthetic analogue of hirudin that reversibly binds to both the active site and the exosite I (fibrinogen-binding site) of thrombin in a bivalent interaction. Unlike argatroban, bivalirudin is cleared by both renal excretion (20%) and proteolytic cleavage by thrombin itself (80%), providing a short half-life of approximately 25 minutes. The thrombin-mediated proteolytic cleavage of bivalirudin is a pharmacokinetically important feature: once bivalirudin is cleaved, the active-site fragment dissociates and thrombin is transiently restored to activity before systemic bivalirudin is eliminated. This is clinically relevant in cardiopulmonary bypass (CPB), where blood stagnation in the circuit allows thrombin to cleave bivalirudin locally, potentially causing clot formation in the bypass circuit; bivalirudin use in on-pump CPB requires meticulous attention to circuit flow and is generally reserved for HIT patients requiring cardiac surgery. In non-cardiac settings, bivalirudin is dosed by continuous IV infusion at 0.15 to 0.2 mg/kg/hr for HIT anticoagulation, titrated to aPTT 1.5 to 2.5 times baseline. Dose reduction is required for significant renal impairment (CrCl below 30 mL/min, reduce by 50 to 60%).12,13
Transition from HIT Anticoagulation to Warfarin. Warfarin can be initiated in HIT patients only after the platelet count has recovered to a stable level above 150 x 109/L, because early warfarin initiation during HIT with a low platelet count risks precipitating microvascular thrombosis and limb gangrene through the same mechanism as warfarin-induced skin necrosis in protein C deficiency: protein C (a vitamin K-dependent anticoagulant protein with a short half-life) falls before procoagulant factors, creating a transient procoagulant state in the setting of already-active thrombin generation. Warfarin should be started at low doses (5 mg or less daily) and overlapped with the alternative anticoagulant for at least 5 days and until the INR has been in the therapeutic range for 2 consecutive measurements, with the argatroban-specific INR correction noted above applied when relevant. The total duration of anticoagulation in HIT without thrombosis is typically 1 to 3 months; with associated thrombosis, at least 3 to 6 months.11,12
Protamine Sulfate Reversal of UFH and LMWH. Protamine sulfate is a polycationic peptide derived from salmon sperm that neutralizes heparin by forming a stable ionic complex with it, rendering the complex biologically inert. The complex is then cleared from circulation. For UFH, 1 mg of protamine neutralizes approximately 100 IU (international units) of UFH; the dose is calculated based on the amount of heparin administered in the preceding 2 to 4 hours (not the total accumulated dose, as heparin has already been partially cleared). For IV UFH infusions, the maximum recommended single dose is 50 mg. Protamine must be administered slowly (over at least 10 minutes) to avoid severe adverse reactions: rapid IV injection causes hypotension, bradycardia, and pulmonary vasoconstriction through complement activation and direct mast cell degranulation. In patients with fish allergy, prior protamine exposure (including NPH (neutral protamine Hagedorn) insulin users who receive protamine-containing preparations), or vasectomy, the risk of anaphylaxis is increased and premedication or alternative reversal strategies should be considered. Protamine partially neutralizes LMWHs: it fully neutralizes the anti-IIa activity of enoxaparin and dalteparin but only partially neutralizes anti-Xa activity (approximately 60 to 80% neutralization); protamine has no significant activity against fondaparinux.1,5,6
Andexanet Alfa. Andexanet alfa (Andexxa) is a recombinant, catalytically inactive modified factor Xa (FXa) decoy protein that binds and sequesters direct FXa inhibitors (rivaroxaban, apixaban, edoxaban), as well as LMWH and fondaparinux anti-Xa activity in the circulation, reversing their anticoagulant effect. Because andexanet alfa is a catalytically inactive FXa decoy without procoagulant activity, it does not generate thrombin directly, but by sequestering active anticoagulant drug molecules it restores endogenous thrombin generation to baseline. Andexanet alfa also binds TFPI (tissue factor pathway inhibitor) released by heparin from the endothelium, which may contribute a secondary procoagulant effect independent of FXa inhibitor reversal. It is approved for reversal of rivaroxaban and apixaban in life-threatening or uncontrolled bleeding; its use for LMWH and fondaparinux reversal is off-label. Dosing is based on the specific FXa inhibitor and the dose and timing of the last administered dose: a low-dose regimen uses a 400 mg IV bolus followed by 480 mg infused over 2 hours; a high-dose regimen uses an 800 mg bolus followed by 960 mg over 2 hours. Thrombotic events following andexanet alfa administration occur in approximately 10 to 15% of treated patients in post-approval cohort data, reflecting the shift from anticoagulated to transiently hypercoagulable state following reversal.7
Argatroban preferred when: renal failure or CrCl <30 mL/min; PCI in HIT. Bivalirudin preferred when: hepatic impairment; cardiac surgery requiring CPB anticoagulation in HIT; short procedures where rapid offset is valuable. Fondaparinux: reasonable option in stable HIT post-acute phase; not first-line in acute thrombotic HIT. Danaparoid (not available in US; available in Canada/Europe): heparinoid with low HIT cross-reactivity; alternative where argatroban/bivalirudin unavailable. Never use LMWH: 90% cross-reactivity with HIT antibodies; will perpetuate platelet activation and thrombosis.
Selecting the appropriate heparin-based anticoagulant for a given clinical indication requires integrating the pharmacological differences between UFH (unfractionated heparin), LMWHs, and fondaparinux with patient-specific factors including renal function, body weight, thromboembolic risk, bleeding risk, and the need for procedural reversal. The following framework addresses the most clinically important indications covered by this drug class.
VTE Prophylaxis. Pharmacological prophylaxis of venous thromboembolism (VTE) in hospitalized patients is one of the most common indications for heparin-based anticoagulants. For surgical patients at moderate VTE risk, subcutaneous UFH at 5,000 IU (international units) every 8 to 12 hours or subcutaneous enoxaparin at 40 mg once daily are equivalent options; enoxaparin is preferred when twice-daily nursing administration is a concern or when anti-Xa monitoring may be needed. For high-risk orthopedic surgery (total hip arthroplasty (THA), total knee arthroplasty (TKA), hip fracture surgery), extended prophylaxis for 10 to 35 days with LMWH (low-molecular-weight heparin), fondaparinux, or a DOAC (direct oral anticoagulant) is guideline-recommended; fondaparinux demonstrated superior VTE prevention compared to enoxaparin in the large PENTATHLON (Fondaparinux prophylaxis trial), PENTATHALON-2000 (fondaparinux vs enoxaparin in knee replacement), and EPHESUS (Efficacy and safety of fondaparinux in hip fracture surgery) trials in orthopedic surgery but carries higher bleeding risk and lacks reversal agent. For medically ill patients, enoxaparin 40 mg once daily or dalteparin 5,000 IU once daily reduces VTE risk and is recommended for patients with reduced mobility and at least one VTE risk factor.514
VTE Treatment. For treatment of acute DVT (deep vein thrombosis) and PE (pulmonary embolism), LMWH has been demonstrated non-inferior to UFH in multiple randomized trials and is the preferred initial anticoagulant for most patients treated outside the ICU setting. UFH retains first-line status for massive PE with hemodynamic instability where thrombolysis may be immediately required (UFH can be stopped and protamine given immediately before lytic therapy, whereas LMWH cannot be rapidly reversed), for PE with severe renal impairment (CrCl below 30 mL/min), and in the inpatient ICU setting where anti-Xa monitoring and dose adjustment may be needed more frequently than subcutaneous LMWH permits. The CLOT (Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for Cancer-Associated Thrombosis) trial established that extended LMWH (dalteparin) was superior to warfarin for preventing recurrent VTE in cancer patients, and this finding has been replicated in subsequent trials; LMWH remains the preferred anticoagulant for cancer-associated VTE in patients where DOAC use is contraindicated or impractical (GI [gastrointestinal] tumors at high bleeding risk, thrombocytopenia from chemotherapy).9,14
Acute Coronary Syndrome Anticoagulation. In ACS (acute coronary syndrome), parenteral anticoagulation with a heparin-based agent or bivalirudin is used during the acute phase to prevent further thrombus propagation and during percutaneous coronary intervention (PCI) to prevent catheter-related thrombosis. For NSTE-ACS (non-ST-elevation ACS) managed with an early invasive strategy, both UFH and enoxaparin are guideline-supported, with enoxaparin demonstrating a modest net clinical benefit over UFH in the SYNERGY (Superior Yield of the New Strategy of Enoxaparin Revascularization and Glycoprotein IIb/IIIa Inhibitors) trial when bleeding and ischemic outcomes were analyzed together. Fondaparinux demonstrated superior efficacy and lower bleeding compared to enoxaparin in the large OASIS-5 (Fifth Organization to Assess Strategies in Acute Ischemic Syndromes) trial for NSTE-ACS, but is associated with catheter thrombosis during PCI if used as the sole anticoagulant, necessitating the addition of UFH for PCI when fondaparinux is the upstream anticoagulant. For STEMI (ST-elevation myocardial infarction) managed with primary PCI (percutaneous coronary intervention), UFH remains the standard anticoagulant intraoperatively, with bivalirudin as an alternative associated with less bleeding at the cost of slightly higher stent thrombosis risk in some analyses.3,14
Bridging Anticoagulation. Bridging anticoagulation refers to the use of a short-acting parenteral anticoagulant to cover the period when long-term oral anticoagulation (classically warfarin) is interrupted for surgery or an invasive procedure. The rationale for bridging is to minimize the time the patient is subtherapeutically anticoagulated in the perioperative period. LMWH (typically enoxaparin at therapeutic dose) is the standard bridging agent. However, the large BRIDGE (Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy) randomized trial demonstrated that in patients with AF (atrial fibrillation) and a CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score of 1 to 3, forgoing bridging anticoagulation was non-inferior to LMWH bridging for preventing thromboembolism while significantly reducing perioperative bleeding. Current guidelines therefore recommend against routine bridging in most AF patients, reserving bridging for patients at very high thromboembolic risk (mechanical heart valves, AF with CHADS2 score of 5 or 6, or recent [within 3 months] stroke or VTE). For mechanical heart valves, therapeutic-dose bridging with UFH or LMWH remains standard practice given the very high stroke risk of even brief anticoagulation interruption.11,14
UFH: aPTT-monitored IV infusion; preferred in renal failure, hemodynamic instability requiring rapid reversal, and cardiac surgery. LMWH: fixed weight-based SC dosing; preferred for outpatient VTE treatment, VTE prophylaxis, cancer-associated thrombosis, and pregnancy. Anti-Xa monitoring required in CrCl <30, obesity, extremes of weight, pregnancy. Fondaparinux: once-daily SC; no HIT risk; no reversal agent; contraindicated CrCl <30 mL/min; preferred VTE prophylaxis post-orthopedic surgery when bleeding risk acceptable. HIT: stop all heparin immediately; initiate argatroban (renal failure preferred) or bivalirudin (hepatic failure preferred); delay warfarin until platelets >150 x 109/L; total anticoagulation duration 1–3 months (no thrombosis) or 3–6 months (with thrombosis). Protamine reversal: 1 mg per 100 IU UFH; slow IV; maximum 50 mg; partial LMWH reversal; no fondaparinux reversal.
Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1 Suppl):64S-94S.
doi:10.1378/chest.119.1_suppl.64SWeitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688-698.
doi:10.1056/NEJM199709043371007Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a standard care nomogram. Ann Intern Med. 1993;119(9):874-881.
doi:10.7326/0003-4819-119-9-199311010-00002Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-684.
doi:10.7326/0003-4819-144-9-200605020-00011Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-e43S.
doi:10.1378/chest.11-2291Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet. 2002;359(9319):1710-1711.
doi:10.1016/S0140-6736(02)08660-9Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-1141.
doi:10.1056/NEJMoa1607887Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: ACCP Guidelines. Chest. 2012;141(2 Suppl):e737S-e801S.
doi:10.1378/chest.11-2308Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92-128.
doi:10.1007/s11239-015-1309-0Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
doi:10.1056/NEJM199505183322003Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392.
doi:10.1182/bloodadvances.2018024489Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
doi:10.1111/j.1538-7836.2006.01787.xLewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838-1843.
doi:10.1161/01.CIR.103.14.1838Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
doi:10.1016/j.chest.2015.11.026